Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice

References

• Ramchandani M, Kong M, Tronstein E, et al. Herpes simplex virus type 1 shedding in tears and nasal and oral mucosa of healthy adults. Sex Transm Dis. 2016;43:756–760.
   Web of Science ®Google Scholar
• Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1–13.
   PubMed Web of Science ®Google Scholar
• Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. 2006;25:355–380.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhu H. Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases. Virol Sin. 2014;29:327–342.
   PubMedGoogle Scholar
• Labetoulle M, Auquier P, Conrad H, et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112:888–895.
   PubMed Web of Science ®Google Scholar
• Al-Dujaili LJ, Clerkin PP, Clement C, et al. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol. 2011;6:877–907.
   PubMed Web of Science ®Google Scholar
• Mustafa M, Muthusaamy P, Hussain SS, et al. Uveitis: pathogenesis, clinical presentations and treatment. IOSR J Pharm. 2014;4:42–47.
   Google Scholar
• Liesegang TJ, Melton LJ 3rd, Daly PJ, et al. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155–1159.
   PubMed Web of Science ®Google Scholar
• Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012;57:448–462.
   PubMed Web of Science ®Google Scholar
• Bradley H, Markowitz LE, Gibson T, et al. Seroprevalence of herpes simplex virus types 1 and 2–United States, 1999-2010. J Infect Dis. 2014;209:325–333.
   PubMed Web of Science ®Google Scholar
• Young RC, Hodge DO, Liesegang TJ, et al. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in olmsted county, minnesota, 1976-2007 the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128:1178–1183.
   PubMedGoogle Scholar
• Goldberg I, Clement CI, Chiang TH, et al. Assessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaire. J Glaucoma. 2009;18:6–12.
   PubMed Web of Science ®Google Scholar
• Reynaud C, Rousseau A, Kaswin G, et al. Persistent impairment of quality of life in patients with herpes simplex keratitis. Ophthalmology. 2017;124:160–169.
   Web of Science ®Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–1058.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615–621.
   PubMed Web of Science ®Google Scholar
• Liu X, Kolli S, McDonnell P, et al. Patient priorities in herpes simplex keratitis. BMJ Open Ophthalmol. 2019;4:e000177.
   Web of Science ®Google Scholar
• Chia EM, Mitchell P, Ojaimi E, et al. Assessment of vision-related quality of life in an older population subsample: The Blue Mountains Eye Study. Ophthalmic Epidemiol. 2006;13:371–377.
   PubMed Web of Science ®Google Scholar
• Looker KJ, Magaret AS, May MT, et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PloS One. 2015;10:e0140765.
   Web of Science ®Google Scholar
• McDonald EM, Patel DV, McGhee CN. A prospective study of the clinical characteristics of patients with herpes simplex and varicella zoster keratitis, presenting to a New Zealand emergency eye clinic. Cornea. 2015;34:279–284.
   Web of Science ®Google Scholar
• Garrity JA, Liesegang TJ. Ocular complications of atopic dermatitis. Can J Ophthalmol. 1984;19:21–24.
   PubMed Web of Science ®Google Scholar
• Young TL, Robin JB, Holland GN, et al. Herpes simplex keratitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1989;96:1476–1479.
   PubMed Web of Science ®Google Scholar
• Souza PM, Holland EJ, Huang AJ. Bilateral herpetic keratoconjunctivitis. Ophthalmology. 2003;110:493–496.
   Web of Science ®Google Scholar
• Hsiao CH, Yeung L, Yeh LK, et al. Pediatric herpes simplex virus keratitis. Cornea. 2009;28:249–253.
   Web of Science ®Google Scholar
• Al-Qarni A, AlHarbi M. Herpetic keratitis after corneal collagen cross-linking with riboflavin and Ultraviolet-A for keratoconus. Middle East Afr J Ophthalmol. 2015;22:389–392.
   Web of Science ®Google Scholar
• Levy J, Lapid-Gortzak R, Klemperer I, et al. Herpes simplex virus keratitis after laser in situ keratomileusis. J Refract Surg. 2005;21:400–402.
   Web of Science ®Google Scholar
• Kaiserman I, Kaiserman N, Nakar S, et al. Herpetic eye disease in diabetic patients. Ophthalmology. 2005;112:2184–2188.
   PubMed Web of Science ®Google Scholar
• Kosker M, Hammersmith KM, Nagra PK, et al. The association between diabetes and herpes simplex eye disease. Ocul Immunol Inflamm. 2018;26:125–129.
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.
   Web of Science ®Google Scholar
• Pollock G. Guidelines for the Medical Selection of Eye Donors. [ cited 2013 Jan 1]. Available from: http://ebaanz.rasidesigns.com/wp-content/uploads/2015/06/EBAANZ_Guidelines_for_the_Medical_Selection_of_Eye_Donors.pdf.
   Google Scholar
• Zealand EBAoAaN. EBAANZ Medical and Quality Standards for Eye Donation and Eye Tissue Banking In, 2009.
   Google Scholar
• Mannis MJ, Plotnik RD, Schwab IR, et al. Herpes simplex dendritic keratitis after keratoplasty. Am J Ophthalmol. 1991;111:480–484.
   Web of Science ®Google Scholar
• Goodfellow JF, Nabili S, Jones MN, et al. Antiviral treatment following penetrating keratoplasty for herpetic keratitis. Eye (Lond). 2011;25:470–474.
   Web of Science ®Google Scholar
• Bhatt UK, Abdul Karim MN, Prydal JI, et al. Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts. Cochrane Database Syst Rev. 2016;11:CD007824.
   PubMedGoogle Scholar
• Williams KA, Keane MC, Coffey NE et al. 2018; The Australian Corneal Graft Registry 2018 report.
   Google Scholar
• Ren Y, Wang H, Zheng Q, et al. Long-term outcomes of deep anterior lamellar keratoplasty treating posterior stroma-implicated herpetic corneal opacities. Cornea. 2016;35:299–304.
   Web of Science ®Google Scholar
• Barequet IS, Wasserzug Y. Herpes simplex keratitis after cataract surgery. Cornea. 2007;26:615–617.
   Web of Science ®Google Scholar
• Patel NN, Teng CC, Sperber Laurence T D., et al. New-onset herpes simplex virus keratitis after cataract surgery. Cornea. 2009;28:108–110.
   Web of Science ®Google Scholar
• Hill GM, Ku ES, Dwarakanathan S. Herpes simplex keratitis. Dis Mon. 2014;60:239–246.
   PubMed Web of Science ®Google Scholar
• Ludema C, Cole SR, Poole C, et al. Association between unprotected ultraviolet radiation exposure and recurrence of ocular herpes simplex virus. Am J Epidemiol. 2014;179:208–215.
   Web of Science ®Google Scholar
• Ives AM, Bertke AS. Stress hormones epinephrine and corticosterone selectively modulate herpes simplex virus 1 (HSV-1) and HSV-2 productive infections in adult sympathetic, but not sensory, neurons. J Virol. 2017;91:e00582–17.
   Web of Science ®Google Scholar
• Vicetti Miguel RD, Sheridan BS, Harvey SA, et al. 17-beta estradiol promotion of herpes simplex virus type 1 reactivation is estrogen receptor dependent. J Virol. 2010;84:565–572.
   Web of Science ®Google Scholar
• Mucci JJ, Utz VM, Galor A, et al. Recurrence rates of herpes simplex virus keratitis in contact lens and non-contact lens wearers. Eye Contact Lens. 2009;35:185–187.
   Web of Science ®Google Scholar
• Rolinski J, Hus I. Immunological aspects of acute and recurrent herpes simplex keratitis. J Immunol Res. 2014;2014:513560.
   Web of Science ®Google Scholar
• Koujah L, Suryawanshi RK, Shukla D. Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea. Cell Mol Life Sci. 2019;76:405–419.
   PubMed Web of Science ®Google Scholar
• Jeon S, St Leger AJ, Cherpes TL, et al. PD-L1/B7-H1 regulates the survival but not the function of CD8+ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia. J Immunol. 2013;190:6277–6286.
   Web of Science ®Google Scholar
• Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc. 2011;86:1009–1026.
   PubMed Web of Science ®Google Scholar
• Toma HS, Murina AT, Areaux RG Jr., et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol. 2008;23:249–273.
   PubMedGoogle Scholar
• Hu K, Harris DL, Yamaguchi T, et al. A dual role for corneal dendritic cells in herpes simplex keratitis: local suppression of corneal damage and promotion of systemic viral dissemination. PloS One. 2015;10:e0137123.
   PubMed Web of Science ®Google Scholar
• Hamrah P, Pavan-Langston D, Dana R. Herpes simplex keratitis and dendritic cells at the crossroads: lessons from the past and a view into the future. Int Ophthalmol Clin. 2009;49:53–62.
   PubMedGoogle Scholar
• Holbach LM, Asano N, Naumann GO. Infection of the corneal endothelium in herpes simplex keratitis. Am J Ophthalmol. 1998;126:592–594.
   Web of Science ®Google Scholar
• White ML, Chodosh J. Herpes simplex virus keratitis: a treatment guideline. Hoskins Center for Quality Eye Care and American Academy of Ophthalmology Website; 2014. Available from https://www.aao.org/clinical-statement/herpes-simplex-virus-keratitis-treatment-guideline
   Google Scholar
• James SH, Whitley RJ. Treatment of herpes simplex virus infections in pediatric patients: current status and future needs. Clin Pharmacol Ther. 2010;88:720–724.
   PubMed Web of Science ®Google Scholar
• Green LK, Pavan-Langston D. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin. 2006;46:27–37.
   Google Scholar
• Gabison EE, Alfonsi N, Doan S, et al. Archipelago keratitis: a clinical variant of recurrent herpetic keratitis? Ophthalmology. 2007;114:2000–2005.
   Web of Science ®Google Scholar
• Gimenez F, Suryawanshi A, Rouse BT. Pathogenesis of herpes stromal keratitis–a focus on corneal neovascularization. Prog Retin Eye Res. 2013;33:1–9.
   PubMed Web of Science ®Google Scholar
• Hamrah P, Alipour F, Jiang S, et al. Optimizing evaluation of Lissamine Green parameters for ocular surface staining. Eye (Lond). 2011;25:1429–1434.
   Web of Science ®Google Scholar
• Tu EY, Joslin CE, Sugar J, et al. Prognostic factors affecting visual outcome in Acanthamoeba keratitis. Ophthalmology. 2008;115:1998–2003.
   PubMed Web of Science ®Google Scholar
• Carnt N, Robaei D, Minassian DC, et al. Acanthamoeba keratitis in 194 patients: risk factors for bad outcomes and severe inflammatory complications. Br J Ophthalmol. 2018;102:1431–1435.
   PubMed Web of Science ®Google Scholar
• Azher TN, Yin XT, Tajfirouz D, et al. Herpes simplex keratitis: challenges in diagnosis and clinical management. Clin Ophthalmol. 2017;11:185–191.
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Karenchak LM, Dhaliwal DK, et al. AmpliVue is a practical and timely test for the detection of HSV from keratitis specimens. Eye Contact Lens. 2018;44(Suppl 1):S244–S248.
   Google Scholar
• Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1883-1895; discussion 1895-1886.
   Web of Science ®Google Scholar
• Dawson CR, Jones DB, Kaufman HE, et al. Design and organization of the herpetic eye disease study (HEDS). Curr Eye Res. 1991;10(Suppl):105–110.
   Google Scholar
• Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1871–1882.
   PubMed Web of Science ®Google Scholar
• Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. Arch Ophthalmol. 1996;114:1065–1072.
   Google Scholar
• Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. Arch Ophthalmol. 1997;115:703–712.
   Google Scholar
• Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol. 2000;118:1030–1036.
   Google Scholar
• Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339:300–306.
   PubMed Web of Science ®Google Scholar
• Herpetic Eye Disease Study Group. Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections. Arch Ophthalmol. 2000;118:1617–1625.
   PubMedGoogle Scholar
• Aiello AE, Simanek AM, Galea S. Population levels of psychological stress, herpesvirus reactivation and HIV. AIDS Behav. 2010;14:308–317.
   PubMed Web of Science ®Google Scholar
• Rooney JF, Bryson Y, Mannix ML, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet. 1991;338:1419–1422.
   PubMed Web of Science ®Google Scholar
• Guinan ME, MacCalman J, Kern ER, et al. The course of untreated recurrent genital herpes simplex infection in 27 women. N Engl J Med. 1981;304:759–763.
   PubMed Web of Science ®Google Scholar
• Spruance SL, Kriesel JD, Evans TG, et al. Susceptibility to herpes labialis following multiple experimental exposures to ultraviolet radiation. Antiviral Res. 1995;28:57–67.
   Web of Science ®Google Scholar
• Micks E, Son H, Magaret A, et al. The effect of hormonal contraception and menstrual cycle timing on genital herpes simplex virus-2 shedding and lesions. Sex Transm Dis. 2019;46:58–62.
   Web of Science ®Google Scholar
• Kalezic T, Mazen M, Kuklinski E, et al. Herpetic eye disease study: lessons learned. Curr Opin Ophthalmol. 2018;29:340–346.
   Web of Science ®Google Scholar
• Cabrera-Aguas M, Kerdraon Y, Symes RJ, et al. Development, Implementation, and Evaluation of Treatment Guidelines for Herpes Simplex Keratitis in Sydney, Australia. Cornea. 2020;39:834–840.
   Google Scholar
• Naito T, Shiota H, Mimura Y. Side effects in the treatment of herpetic keratitis. Curr Eye Res. 1987;6:237–239.
   PubMed Web of Science ®Google Scholar
• Millan-Parrilla F, de la Cuadra J. Allergic contact dermatitis from trifluoridine in eyedrops. Contact Dermatitis. 1990;22:289.
   Web of Science ®Google Scholar
• Poole CL, James SH. Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther. 2018;40:1282–1298.
   PubMed Web of Science ®Google Scholar
• Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014;10:665–681.
   PubMed Web of Science ®Google Scholar
• Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55:459–472.
   PubMed Web of Science ®Google Scholar
• Duan R, de Vries RD, Osterhaus AD, et al. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis. 2008;198:659–663.
   PubMed Web of Science ®Google Scholar
• Sahin A, Hamrah P. Acute herpetic keratitis: what is the role for ganciclovir ophthalmic gel? Ophthalmol Eye Dis. 2012;4:23–34.
   Google Scholar
• Wang X, Wang L, Wu N, et al. Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis. Chin Med J (Engl). 2015;128:46–50.
   Web of Science ®Google Scholar
• Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2016;12:CD002898.
   Google Scholar
• Patterson A, Jones BR. The management of ocular herpes. Trans Ophthalmol Soc U K. 1967;87:59–84.
   PubMedGoogle Scholar
• Meng JB, Zheng X, Zhang G, et al. Oral acyclovir induced acute renal failure. World J Emerg Med. 2011;2:310–313.
   Google Scholar
• Collum LM, McGettrick P, Akhtar J, et al. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol. 1986;70:435–438.
   PubMed Web of Science ®Google Scholar
• Hung SO, Patterson A, Rees PJ. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol. 1984;68:192–195.
   PubMed Web of Science ®Google Scholar
• Shimeld C, Tullo AB, Easty DL, et al. Isolation of herpes simplex virus from the cornea in chronic stromal keratitis. Br J Ophthalmol. 1982;66:643–647.
   PubMed Web of Science ®Google Scholar
• Guess S, Stone DU, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf. 2007;5:240–250.
   PubMed Web of Science ®Google Scholar
• Peyman A, Nayebzadeh M, Peyman M, et al. Topical cyclosporine-A versus prednisolone for herpetic stromal keratitis: a randomized controlled trial. Acta Ophthalmol. 2019;97:e194–e198.
   Web of Science ®Google Scholar
• Yoon JC, Cho JJ, Yoo SM, et al. Antiviral activity of ascorbic acid against herpes simplex virus. J Korean Soc Microbiol. 2000;35:1–8.
   Google Scholar
• Kim G-N, Yoo W-S, Park M-H, et al. Clinical features of herpes simplex keratitis in a korean tertiary referral center: efficacy of oral antiviral and ascorbic acid on recurrence. Korean J Ophthalmol. 2018;32:353–360.
   PubMedGoogle Scholar
• Lobo V, Patil A, Phatak A, et al. Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev. 2010;4:118–126.
   PubMedGoogle Scholar
• Furuya A, Uozaki M, Yamasaki H, et al. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. Int J Mol Med. 2008;22:541–545.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Galli L, et al. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol. 2007;144:547–551.
   PubMed Web of Science ®Google Scholar
• Pinder M, Wright A. Valaciclovir versus aciclovir for the treatment of primary genital herpes simplex: a cost analysis. Int J STD AIDS. 2015;26:971–973.
   Web of Science ®Google Scholar
• Rousseau A, Boutolleau D, Titier K, et al. Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study. Antiviral Res. 2017;146:205–212.
   Web of Science ®Google Scholar
• Kim JH, Seo HW, Han HC, et al. The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study. Korean J Ophthalmol. 2013;27:235–242.
   Google Scholar
• Romano V, Steger B, Kaye SB. Fine-needle diathermy guided by angiography. Cornea. 2015;34:e29–30.
   Web of Science ®Google Scholar
• Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–579.
   PubMedGoogle Scholar
• Moein HR, Kheirkhah A, Muller RT, et al. Corneal nerve regeneration after herpes simplex keratitis: A longitudinal in vivo confocal microscopy study. Ocul Surf. 2018;16:218–225.
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125:1332–1343.
   PubMed Web of Science ®Google Scholar
• Sheha H, Tighe S, Hashem O, et al. Update on cenegermin eye drops in the treatment of neurotrophic keratitis. Clin Ophthalmol. 2019;13:1973–1980.
   Web of Science ®Google Scholar
• Versura P, Giannaccare G, Pellegrini M, et al. Neurotrophic keratitis: current challenges and future prospects. Eye Brain. 2018;10:37–45.
   PubMed Web of Science ®Google Scholar
• Awasthi S, Hook LM, Pardi N, et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol. 2019;4:eaaw7083.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Levin MJ. Herpes zoster vaccines. J Infect Dis. 2018;218:S127–S133.
   Web of Science ®Google Scholar
• Dasgupta G, Chentoufi AA, Nesburn AB, et al. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines. 2009;8:1023–1035.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43.
   PubMed Web of Science ®Google Scholar
• Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, et al. Herpes simplex virus vaccine in recurrent herpetic ocular infection. Cornea. 1999;18:47–51.
   PubMed Web of Science ®Google Scholar
• Dervillez X, Gottimukkala C, Kabbara KW, et al. Future of an “Asymptomatic” T-cell epitope-based therapeutic herpes simplex vaccine. Future Virol. 2012;7:371–378.
   PubMed Web of Science ®Google Scholar
• Royer DJ, Cohen A, Carr D. The current state of vaccine development for ocular HSV-1 infection. Expert Rev Ophthalmol. 2015;10:113–126.
   PubMed Web of Science ®Google Scholar